Post-traumatic stress disorder (PTSD) can develop following a traumatic event and
results in heightened fear and anxiety. Although approximately 8% of the US population
suffers from PTSD, only two drugs have been approved by the FDA to treat it, both
with limited efficacy. Propranolol, a non-selective β-adrenergic antagonist, has shown
efficacy in decreasing exaggerated fear, and there has been renewed interest in using
it to treat fear disorders.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Biological PsychiatryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2020 Published by Elsevier Inc.
